BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression

• Published in: British journal of cancer 2009-10, Vol.101 (7), p.1168-1174
• Main Authors: Yan, M, Rayoo, M, Takano, E A, Thorne, H, Fox, S B
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cancer Research; Drug Resistance; Epidemiology; Molecular Diagnostics; Molecular Medicine; Oncology
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6605287

Background: There are limited data regarding the hypoxia pathway in familial breast cancers. We therefore performed a study of hypoxic factors in BRCA1, BRCA2 and BRCAX breast cancers. Methods: Immunoperoxidase staining for HIF-1 α , PHD1, PHD2, PHD3, VEGF and FIH was carried out in 125 (38 BRCA1, 33 BRCA2 and 54 BRCAX) breast carcinomas. These were correlated with clinicopathological parameters and the intrinsic breast cancer phenotypes. Results: BRCA1 tumours correlated with positivity for HIF-1 α ( P =0.008) and negativity for PHD3 ( P =0.037). HIF-1 α positivity ( P =0.001), PHD3 negativity ( P =0.037) and nuclear FIH negativity ( P =0.011) was associated with basal phenotype. HIF-1 α expression correlated with high tumour grade ( P =0.009), negative oestrogen receptor (ER) status ( P =0.001) and the absence of lymph node metastasis ( P =0.028). Nuclear FIH expression and PHD3 correlated with positive ER expression ( P =0.024 and P =0.035, respectively). BRCA1 cancers with positive HIF-1 α or cytoplasmic FIH had a significantly shorter relapse-free survival ( P =0.007 and P =0.049, respectively). Conclusions: The aggressive nature of BRCA1 and basal-type tumours may be partly explained by an enhanced hypoxic drive and hypoxia driven ER degradation because of suppressed PHD and aberrantly located FIH expression. This may have important implications, as these tumours may respond to compounds directed against HIF-1 α or its downstream targets.